Elevation Oncology (NASDAQ:ELEV) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for patients with genomically defined cancers. Leveraging a biomarker-driven approach, the company designs targeted small molecules and antibody–drug conjugates that address oncogenic drivers such as gene fusions, splice variants and kinase mutations. Elevation Oncology’s mission is to deliver novel medicines to patient populations underserved by existing treatments, with lead programs currently advancing through Phase 1 and Phase 2 clinical trials.
The company’s product pipeline centers on three core assets. The first, EO-101, is a selective inhibitor designed to block aberrant signaling in tumors harboring RTK fusions. The second program, EO-102, is an antibody–drug conjugate engineered to home in on NRG1 fusion‐positive cancers. A third, EO-103, is a small‐molecule inhibitor aimed at FGFR gene alterations. Elevation Oncology has established collaborations with leading academic centers and diagnostic laboratories to identify eligible patients via next-generation sequencing panels, ensuring that each investigational therapy is matched to its most responsive population.
Founded in 2019 and headquartered in San Diego, California, Elevation Oncology was created by a team of oncology veterans and molecular biologists committed to translating genomic insights into patient benefit. Chief Executive Officer Samuel L. Jacobs, Ph.D., previously led early‐stage oncology programs at Gilead Sciences, while Chief Medical Officer Dr. Anita R. Patel brings extensive experience overseeing global cancer trials. The company’s scientific advisory board includes experts from MD Anderson Cancer Center and the Broad Institute, providing guidance on trial design, biomarker development and regulatory strategy.
Elevation Oncology conducts multi‐regional clinical trials across North America, Europe and Asia, with a network of over 50 oncology centers collaborating on protocol execution and patient enrollment. In parallel with its clinical efforts, the company pursues strategic partnerships and licensing agreements to expand its pipeline and accelerate the path to approval. Through this integrated development model, Elevation Oncology aims to address high-unmet needs in precision oncology and bring transformative treatments to patients worldwide.
